The peak-flux of GRB 221009A measured with GRBAlpha

The brightest gamma-ray burst ever observed, long-duration GRB 221009A, was detected by GRBAlpha nano-satellite without saturation. We present light curves of the prompt emission in 13 energy bands, from 80 keV to 950 keV, and perform a spectral analysis to calculate the peak flux and peak isotropic-equivalent luminosity. Since the satellite's attitude information is not available for the time of this GRB, more than 200 incident directions were probed in order to find the median luminosity and its systematic uncertainty. We found that the peak flux in the $80-800$ keV range (observer frame) was $F_{\rm{ph}}^{\rm{p}}=1300_{-200}^{+1200}$ ph cm$^{-2}$s$^{-1}$ or $F_{\rm{erg}}^{\rm{p}}=5.7_{-0.7}^{+3.7}\times10^{-4}$ erg cm$^{-2}$s$^{-1}$ and the fluence in the same energy range of the first GRB episode lasting 300 s, which was observable by GRBAlpha, was $S=2.2_{-0.3}^{+1.4}\times10^{-2}$ erg cm$^{-2}$ or $S^{\rm{bol}}=4.9_{-0.5}^{+0.8}\times10^{-2}$ erg cm$^{-2}$ for the extrapolated range of $0.9-8,690$ keV. We infer the isotropic-equivalent released energy of the first GRB episode to be $E_{\rm{iso}}^{\rm{bol}}=2.8_{-0.5}^{+0.8}\times10^{54}$ erg in the $1-10,000$ keV band (rest frame at $z=0.15$). The peak isotropic-equivalent luminosity in the $92-920$ keV range (rest frame) was $L_{\rm{iso}}^{\rm{p}}=3.7_{-0.5}^{+2.5}\times10^{52}$ erg s$^{-1}$ and the bolometric peak isotropic-equivalent luminosity was $L_{\rm{iso}}^{\rm{p,bol}}=8.4_{-1.5}^{+2.5}\times10^{52}$ erg s$^{-1}$ (4 s scale) in the $1-10,000$ keV range (rest frame). The peak emitted energy is $E_p^\ast=E_p(1+z)=1120\pm470$ keV. Our measurement of $L_{\rm{iso}}^{\rm{p,bol}}$ is consistent with the Yonetoku relation. It is possible that, due to the spectral evolution of this GRB and orientation of GRBAlpha at the peak time, the true values of peak flux, fluence, $L_{\rm{iso}}$, and $E_{\rm{iso}}$ are even higher. [abridged]Comment: 7 pages, 7 figures, 1 table, accepted for publication in Astronomy & Astrophysic

GRBAlpha: the smallest astrophysical space observatory -- Part 1: Detector design, system description and satellite operations

Aims. Since launched on 2021 March 22, the 1U-sized CubeSat GRBAlpha operates and collects scientific data on high-energy transients, making it the smallest astrophysical space observatory to date. GRBAlpha is an in-obit demonstration of a gamma-ray burst (GRB) detector concept suitably small to fit into a standard 1U volume. As it was demonstrated in a companion paper, GRBAlpha adds significant value to the scientific community with accurate characterization of bright GRBs, including the recent outstanding event of GRB 221009A. Methods. The GRB detector is a 75x75x5 mm CsI(Tl) scintillator wrapped in a reflective foil (ESR) read out by an array of SiPM detectors, multi-pixel photon counters by Hamamatsu, driven by two separate, redundant units. To further protect the scintillator block from sunlight and protect the SiPM detectors from particle radiation, we apply a multi-layer structure of Tedlar wrapping, anodized aluminium casing and a lead-alloy shielding on one edge of the assembly. The setup allows observations of gamma radiation within the energy range of 70-890 keV with an energy resolution of ~30%. Results. Here, we summarize the system design of the GRBAlpha mission, including the electronics and software components of the detector, some aspects of the platform as well as the current way of semi-autonomous operations. In addition, details are given about the raw data products and telemetry in order to encourage the community for expansion of the receiver network for our initiatives with GRBAlpha and related experiments.Comment: Accepted for publication in Astronomy & Astrophysics, 9 pages, 10 figure

Experimental Granulometric Characterization of Wood Particles from CNC Machining of Chipboard

The aim of this paper is to determine the particle size composition of the wood particles obtained from CNC milling the chipboard using an experimental optical granulometric method. Composite materials (chipboard) are the most-used materials in the woodworking and furniture industries. The proposed optical method of measuring particles’ dimensions is compared to the sieving technique. The researched experimental method allows for the determination of not only the size of the fraction of an individual particle’s fraction but also more detailed information about the analyzed wood dust emission, for example, the largest and smallest dimension of each single particle; its circularity, area, perimeter, eccentricity, and convex hull major and minor axis length; or the color of the particle

GRBAlpha: The smallest astrophysical space observatory

Aims. Since it launched on 22 March 2021, the 1U-sized CubeSat GRBAlpha operates and collects scientific data on high-energy transients, making it the smallest astrophysical space observatory to date. GRBAlpha is an in-orbit demonstration of a gamma-ray burst (GRB) detector concept suitably small to fit into a standard 1U volume. As was demonstrated in a companion paper, GRBAlpha adds significant value to the scientific community with accurate characterization of bright GRBs, including the recent outstanding event of GRB 221009A. Methods. The GRB detector is a 75 × 75 × 5 mm CsI(Tl) scintillator wrapped in a reflective foil (ESR) read out by an array of SiPM detectors, multi-pixel photon counters by Hamamatsu, driven by two separate redundant units. To further protect the scintillator block from sunlight and protect the SiPM detectors from particle radiation, we applied a multi-layer structure of Tedlar wrapping, anodized aluminium casing, and a lead-alloy shielding on one edge of the assembly. The setup allows observations of gamma radiation within the energy range of 70–890 keV with an energy resolution of ~30%. Results. Here, we summarize the system design of the GRBAlpha mission, including the electronics and software components of the detector, some aspects of the platform, and the current semi-autonomous operations. In addition, details are given about the raw data products and telemetry in order to encourage the community to expand the receiver network for our initiatives with GRBAlpha and related experiments

Review of Research into Enterprise Bankruptcy Prediction in Selected Central and Eastern European Countries

In developed countries, the first studies on forecasting bankruptcy date to the early 20th century. In Central and Eastern Europe, due to, among other factors, the geopolitical situation and the introduced economic system, this issue became the subject of researcher interest only in the 1990s. Therefore, it is worthwhile to analyze whether these countries conduct bankruptcy risk assessments and what their level of advancement is. The main objective of the article is the review and assessment of the level of advancement of bankruptcy prediction research in countries of the former Eastern Bloc, in comparison to the latest global research trends in this area. For this purpose, the method of analyzing scientific literature was applied. The publications chosen as the basis for the research were mainly based on information from the Google Scholar and ResearchGate databases during the period Q4 2016–Q3 2017. According to the author’s knowledge, this is the first such large-scale study involving the countries of the former Eastern Bloc—which includes the following states: Poland, Lithuania, Latvia, Estonia, Ukraine, Hungary, Russia, Slovakia, Czech Republic, Romania, Bulgaria, and Belarus. The results show that the most advanced research in this area is conducted in the Czech Republic, Poland, Slovakia, Estonia, Russia, and Hungary. Belarus Bulgaria and Latvia are on the other end. In the remaining countries, traditional approaches to predicting business insolvency are generally used

Ofatumumab versus Teriflunomide in Multiple Sclerosis

BACKGROUND: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known. METHODS: In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiple sclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks after 20-mg loading doses at days 1, 7, and 14) or oral teriflunomide (14 mg daily) for up to 30 months. The primary end point was the annualized relapse rate. Secondary end points included disability worsening confirmed at 3 months or 6 months, disability improvement confirmed at 6 months, the number of gadolinium-enhancing lesions per T1-weighted magnetic resonance imaging (MRI) scan, the annualized rate of new or enlarging lesions on T2-weighted MRI, serum neurofilament light chain levels at month 3, and change in brain volume. RESULTS: Overall, 946 patients were assigned to receive ofatumumab and 936 to receive teriflunomide; the median follow-up was 1.6 years. The annualized relapse rates in the ofatumumab and teriflunomide groups were 0.11 and 0.22, respectively, in trial 1 (difference, -0.11; 95% confidence interval [CI], -0.16 to -0.06; P<0.001) and 0.10 and 0.25 in trial 2 (difference, -0.15; 95% CI, -0.20 to -0.09; P<0.001). In the pooled trials, the percentage of patients with disability worsening confirmed at 3 months was 10.9% with ofatumumab and 15.0% with teriflunomide (hazard ratio, 0.66; P = 0.002); the percentage with disability worsening confirmed at 6 months was 8.1% and 12.0%, respectively (hazard ratio, 0.68; P = 0.01); and the percentage with disability improvement confirmed at 6 months was 11.0% and 8.1% (hazard ratio, 1.35; P = 0.09). The number of gadolinium-enhancing lesions per T1-weighted MRI scan, the annualized rate of lesions on T2-weighted MRI, and serum neurofilament light chain levels, but not the change in brain volume, were in the same direction as the primary end point. Injection-related reactions occurred in 20.2% in the ofatumumab group and in 15.0% in the teriflunomide group (placebo injections). Serious infections occurred in 2.5% and 1.8% of the patients in the respective groups. CONCLUSIONS: Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, NCT02792218 and NCT02792231.)

Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy

BACKGROUND: the survival benefit of a strategy of coronary-artery bypass grafting (CABG) added to guideline-directed medical therapy, as compared with medical therapy alone, in patients with coronary artery disease, heart failure, and severe left ventricular systolic dysfunction remains unclear. METHODS: From July 2002 to May 2007, a total of 1212 patients with an ejection fraction of 35% or less and coronary artery disease amenable to CABG were randomly assigned to undergo CABG plus medical therapy (CABG group, 610 patients) or medical therapy alone (medical-therapy group, 602 patients). The primary outcome was death from any cause. Major secondary outcomes included death from cardiovascular causes and death from any cause or hospitalization for cardiovascular causes. The median duration of follow-up, including the current extended-follow-up study, was 9.8 years. RESULTS: A primary outcome event occurred in 359 patients (58.9%) in the CABG group and in 398 patients (66.1%) in the medical-therapy group (hazard ratio with CABG vs. medical therapy, 0.84; 95% confidence interval [CI], 0.73 to 0.97; P=0.02 by log-rank test). A total of 247 patients (40.5%) in the CABG group and 297 patients (49.3%) in the medical-therapy group died from cardiovascular causes (hazard ratio, 0.79; 95% CI, 0.66 to 0.93; P=0.006 by log-rank test). Death from any cause or hospitalization for cardiovascular causes occurred in 467 patients (76.6%) in the CABG group and in 524 patients (87.0%) in the medical-therapy group (hazard ratio, 0.72; 95% CI, 0.64 to 0.82; P&lt;0.001 by log-rank test). CONCLUSIONS: In a cohort of patients with ischemic cardiomyopathy, the rates of death from any cause, death from cardiovascular causes, and death from any cause or hospitalization for cardiovascular causes were significantly lower over 10 years among patients who underwent CABG in addition to receiving medical therapy than among those who received medical therapy alone. (Funded by the National Institutes of Health; STICH [and STICHES] ClinicalTrials.gov number, NCT00023595)